Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315288 | 0.87 | PDGFRB (0.49) | TNFPIK3CAGRM4NPSR1ALDH1A1 | |
| SCHEMBL6318862 | 0.87 | DHFR (0.56) | TNFPIK3CAGRM4NPSR1KDR | |
| SCHEMBL6313731 | 0.85 | PIK3CA (0.41) | TNFPIK3CAKMT2AGRM4NPSR1 | |
| SCHEMBL6312550 | 0.84 | CA12 (0.56) | TNFPIK3CAKMT2AGRM4ALPL | |
| SCHEMBL6314083 | 0.84 | BCL6 (0.44) | TNFPIK3CAMEN1KMT2AGRM4 | |
| SCHEMBL6320672 | 0.82 | MAPT (0.50) | PIK3CAKMT2ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL6317775 | 0.81 | BCL6 (0.42) | TNFPIK3CAMEN1KMT2AGRM4 | |
| SCHEMBL6312244 | 0.80 | CYP1A2 (0.52) | TNFPIK3CAMEN1KMT2AALDH1A1 | |
| SCHEMBL6313258 | 0.80 | DYRK1A (0.43) | TNFPIK3CAGRM4NPSR1BCL6 | |
| SCHEMBL6313126 | 0.80 | HTR3A (0.52) | PIK3CAMAPTSMN1; SMN2EGFRDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | TNF 3038/4885PIK3CA 423/4885MEN1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.